GlassScriptPhysician profile
Jason B Dickerson
NPI 1528039377
$2,865.14
in general payments reported to CMS, 2019-2025
32 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 76% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $28.06 · 2021: $104 · 2022: $87.75 · 2023: $190 · 2024: $950 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Long Term Medical Supply Or Device Loan: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.59 |
| Long Term Medical Supply Or Device Loan | $426.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $645.43 | 2021-2025 | Allomatrix, Citrefix, Flexband |
| Trimed, INC. | $634.63 | 2024 | |
| Integra Lifesciences Corporation | $484.79 | 2021-2025 | Integra, Micromatrix, Integra Dermal Regeneration Template |
| Depuy Synthes Sales INC. | $124.64 | 2019-2024 | Motoband, Motoband Cp, Minibunion |
| Vertex Pharmaceuticals Incorporated | $98.62 | 2025 | |
| Linvatec Corporation | $97.77 | 2023 | Biobrace 23mm |
| Boston Scientific Corporation | $82.66 | 2019-2022 | |
| Bioventus LLC | $63.27 | 2023-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $57.59 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System |
| Orthofix Medical, INC. | $56.30 | 2023-2025 | Physio-Stim |
| Vilex LLC | $55.28 | 2021 | |
| Biocomposites INC | $45.06 | 2024-2025 | Stimulan |
| Ani Pharmaceuticals, INC. | $39.26 | 2025 | Purified Cortrophin Gel |
| Globus Medical, INC. | $37.40 | 2025 | Senza |
| Acera Surgical, INC. | $30.08 | 2025 | Restrata Wound Matrix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $29.85 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.42 | 2025 | Exparel, Iovera |
| Averitas Pharma INC. | $23.95 | 2025 | Qutenza |
| Nevro Corp. | $23.90 | 2023 | Senza |
| Medtronic, INC. | $19.63 | 2023 | Intellis Adaptivestim |
| Heron Therapeutics, INC. | $19.27 | 2021 | |
| Sanara Medtech INC. | $18.33 | 2025 | Biasurge |
| Anika Therapeutics, INC. | $18.32 | 2024 | Integrity, Toe Motion, Sports Medicine |
| Solventum Corporation | $17.59 | 2025 | Activ.A.C. |
| Paragon 28, INC. | $17.25 | 2024 | Grappler |
| Tactile Systems Technology INC | $16.98 | 2025 | Flexitouch Plus, Nimbl |
| Treace Medical Concepts, INC. | $16.14 | 2024 | |
| Mimedx Group, INC. | $15.50 | 2025 | |
| Acell, INC. | $15.36 | 2020 | |
| Zimmer Biomet Holdings, INC. | $13.63 | 2025 | A.L.P.S. |
| Merck Sharp & Dohme LLC | $11.61 | 2019 | |
| Arthrosurface Incorporated | $10.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Dickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.